Key facts
- This page summarizes William Conkling's Form 4 filing for Cyclo Therapeutics, Inc. (CYTH).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 05 Jun 2024, 17:07.
William Conkling - 03 Jun 2024 Form 4 Insider Report for Cyclo Therapeutics, Inc. (CYTH)
- Reporting relationship
- Director
- Issuer ticker
- CYTH
- Reported as of
- 03 Jun 2024
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 05 Jun 2024, 17:07:34 UTC
- Prior SEC filing
- 25 Mar 2024
- Next SEC filing
- 25 Jun 2024
- Source filing
- View source filing
- Reporting owner signature
- /s/ William Conkling
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
William Conkling filed Form 4 for Cyclo Therapeutics, Inc. (CYTH) on 05 Jun 2024.
Change
- Previous filing in this sequence was filed on 25 Mar 2024.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
CYTH
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +8,594
- Change %
- +53%
- Price
- $0.000000
- Shares after
- 24,839
- Date
- 03 Jun 2024
- Ownership
- Direct
- Footnotes
- F1
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
CYTH
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +15,562
- Change %
- Price
- $0.000000
- Shares after
- 15,562
- Date
- 03 Jun 2024
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 15,562
- Exercise price
- $1.28
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Represents the grant of fully-vested shares of common stock that the Reporting Person elected to receive in lieu of cash compensation under the issuer's non-employee director compensation policy. Grant reflects director compensation for the first quarter of 2024. The number of shares received in lieu of cash was calculated based on the closing price of $1.28 per share of common stock on June 3, 2024.
Footnote F2
The option vests over a one year period in equal quarterly installments.